Bildkälla: Stockfoto

Medivir: Strategic Pipeline Prioritisation at IGM Biosciences - Redeye

Redeye comments on the cost reduction program at IGM Biosciences which impacts birinapant, which is licensed from Medivir.

Redeye comments on the cost reduction program at IGM Biosciences which impacts birinapant, which is licensed from Medivir.
Börsvärldens nyhetsbrev
ANNONSER